The French state will soon partially reimburse the cost of weight-loss drugs Wegovy and Mounjaro for severely obese patients, expanding access to the expensive drugs, two informed sources told AFP on Wednesday.
Wegovy, produced by Danish pharmaceutical company Novo Nordisk, and Eli Lilly's Mounjaro are among a new generation of weight-loss drugs that have proven remarkably effective, hugely popular and lucrative in the past few years, though they do have some drawbacks.
Health Minister Stephanie Rist is set to announce the reimbursement scheme, set at 65 percent, on Thursday, before it is published in the official journal of new legislation the following day, the sources said.
Patients with severe to morbid obesity will be eligible from mid-June.
High prices for the drugs have been a longstanding problem all over the world including France, where patients pay around €300 a month out of pocket for the injections.
